Samyang Biopharm Corporation
Financials
Valuation Metrics
Samyang Biopharm Corporation's Market Cap is ₩3309B. Ranked #610 of 2,436 in KR market (top 25%), #371 of 787 on KOSPI (top 47%), #67 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 29%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 330.90B KRW | KR#610/2,436 Sec#67/234 |
| Revenue | 28.59B KRW | KR#2,047/2,436 Sec#143/234 |
| Net Income | 2.24B KRW | KR#1,333/2,436 Sec#94/234 |
| Total Assets | 339.28B KRW | KR#941/2,436 Sec#59/234 |
| Net Assets | 234.73B KRW | KR#839/2,436 Sec#56/234 |
| Value | ||
| P/E | 147.95x | KR#1,458/2,436 Sec#98/234 |
| P/B | 1.41x | KR#1,701/2,436 Sec#120/234 |
| P/S | 11.57x | KR#2,283/2,436 Sec#164/234 |
| EV/EBITDA | 140.84x | KR#1,494/2,436 Sec#105/234 |
| FCF Yield | 0.92% | KR#1,142/2,436 Sec#83/234 |
| Profitability | ||
| ROE | 0.95% | KR#1,429/2,436 Sec#98/234 |
| ROA | 0.66% | KR#1,385/2,436 Sec#97/234 |
| Op. Margin | 9.41% | KR#528/2,436 Sec#49/234 |
| Financial Health | ||
| Debt Ratio | 144.54% | KR#1,118/2,436 Sec#127/234 |
| Total Debt | 77.82B KRW | KR#807/2,436 Sec#55/234 |
| FCF | 3.05B KRW | KR#1,016/2,436 Sec#72/234 |
| Cash | 29.68B KRW | KR#1,012/2,436 Sec#66/234 |
| Current Ratio | 1.68x | KR#1,163/2,436 Sec#127/234 |
| Net Debt/EBITDA | 17.89x | KR#1,410/2,436 Sec#98/234 |
| Performance | ||
| 1M Return | -7.10% | KR#1,939/2,436 Sec#184/234 |
| From 52W High | -70.51% | KR#2,206/2,436 Sec#199/234 |
| 1Y MDD | -76.24% | KR#2,193/2,436 Sec#200/234 |
| Trading | ||
| Volume | 46,811 shares | KR#1,485/2,436 Sec#144/234 |
| Foreign Own. | 4.43% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 1,861 KRW | KR#418/2,436 Sec#26/234 |
| BPS | 31,937 KRW | KR#332/2,436 Sec#21/234 |
Company Info
Samyang Biopharm is a company operating in the pharmaceutical bio business, newly established through a spin-off from Samyang Holdings. It develops new drugs and improved new drugs based on innovative technologies, including drug delivery platforms (DDS), polymer nanoparticle technology, and siRNA/mRNA-based delivery technology. The company holds the top position in the domestic cytotoxic anticancer drug market (with Genexol, Pemed) and the global biodegradable suture thread market, demonstrating high technological capabilities and market share. Samyang Biopharm was established in 2025 and is headquartered in Seongnam-si, Gyeonggi-do.